transitioning from tirzepatide to semaglutide Switching Transitioning Treatments: What to Expect

Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)

After the administration of single doses of PF-06882961, exploratory analyses revealed a trend for declining post-dose glucose levels at higher doses, with an apparent dose-related trend observed at 24 hours post dose (Fig

Prioritizing protein and complex carbohydrates Protein is the building block of muscle, and muscle is your primary metabolic engine

For consumers, the take-home message is balanced: there is enough reassurance to support use in appropriate patients, but not enough reason to dismiss the warning entirely